Skip to main content
. 2018 Aug 13;4:82. doi: 10.1038/s41420-018-0084-z

Fig. 2. Effects of regorafenib, SC-43, and SC-78 on active STAT3 levels in HCT-116 and HT-29 cells.

Fig. 2

a Total lysates (30 μg) were prepared from HCT-116 cells after treatment with DMSO (vehicle) or different doses (0.5, 1, 2, and 4 µM) of regorafenib, SC-43, and SC-78 for 24 h and subjected to western blot analyses using primary antibodies against pSTAT3 and STAT3. b Total lysates were also prepared from HT-29 cells after treatment with DMSO or different doses of regorafenib, SC-43, and SC-78 for 6 h and IL-6 (25 ng/ml) for another 30 min and subjected to western blot analyses using the two primary antibodies. Data (lower panels) are the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001 compared with DMSO-treated cells by Student’s t-test